ATE380019T1 - Abgabe eines nsaid aus embolischen mitteln - Google Patents
Abgabe eines nsaid aus embolischen mittelnInfo
- Publication number
- ATE380019T1 ATE380019T1 AT04713577T AT04713577T ATE380019T1 AT E380019 T1 ATE380019 T1 AT E380019T1 AT 04713577 T AT04713577 T AT 04713577T AT 04713577 T AT04713577 T AT 04713577T AT E380019 T1 ATE380019 T1 AT E380019T1
- Authority
- AT
- Austria
- Prior art keywords
- polymer
- nsaid
- delivery
- embolic agents
- uterine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Processing Of Solid Wastes (AREA)
- Materials For Medical Uses (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03251075 | 2003-02-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE380019T1 true ATE380019T1 (de) | 2007-12-15 |
Family
ID=32892983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04713577T ATE380019T1 (de) | 2003-02-21 | 2004-02-23 | Abgabe eines nsaid aus embolischen mitteln |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20060057198A1 (de) |
| EP (1) | EP1594472B1 (de) |
| AT (1) | ATE380019T1 (de) |
| CA (1) | CA2516736A1 (de) |
| DE (1) | DE602004010492T2 (de) |
| ES (1) | ES2298724T3 (de) |
| WO (1) | WO2004073688A1 (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030212022A1 (en) * | 2001-03-23 | 2003-11-13 | Jean-Marie Vogel | Compositions and methods for gene therapy |
| DE01918975T1 (de) * | 2000-03-24 | 2006-04-13 | Biosphere Medical, Inc., Rockland | Mikrokügelchen zur aktiven Embolisierung |
| US7094369B2 (en) | 2002-03-29 | 2006-08-22 | Scimed Life Systems, Inc. | Processes for manufacturing polymeric microspheres |
| US7131997B2 (en) | 2002-03-29 | 2006-11-07 | Scimed Life Systems, Inc. | Tissue treatment |
| US7462366B2 (en) | 2002-03-29 | 2008-12-09 | Boston Scientific Scimed, Inc. | Drug delivery particle |
| US7053134B2 (en) | 2002-04-04 | 2006-05-30 | Scimed Life Systems, Inc. | Forming a chemically cross-linked particle of a desired shape and diameter |
| US7449236B2 (en) | 2002-08-09 | 2008-11-11 | Boston Scientific Scimed, Inc. | Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient |
| US7588825B2 (en) | 2002-10-23 | 2009-09-15 | Boston Scientific Scimed, Inc. | Embolic compositions |
| US7901770B2 (en) | 2003-11-04 | 2011-03-08 | Boston Scientific Scimed, Inc. | Embolic compositions |
| US7311861B2 (en) | 2004-06-01 | 2007-12-25 | Boston Scientific Scimed, Inc. | Embolization |
| WO2006013376A2 (en) * | 2004-08-04 | 2006-02-09 | Biocompatibles Uk Limited | Drug delivery of a cox inhibitor from embolic agents |
| US7963287B2 (en) | 2005-04-28 | 2011-06-21 | Boston Scientific Scimed, Inc. | Tissue-treatment methods |
| US20060251581A1 (en) * | 2005-05-09 | 2006-11-09 | Mcintyre Jon T | Method for treatment of uterine fibroid tumors |
| KR20140090270A (ko) | 2005-05-09 | 2014-07-16 | 바이오스피어 메디칼 에스.에이. | 마이크로스피어 및 비이온성 조영제를 사용하는 조성물 및 방법 |
| US9463426B2 (en) | 2005-06-24 | 2016-10-11 | Boston Scientific Scimed, Inc. | Methods and systems for coating particles |
| US7501179B2 (en) | 2005-12-21 | 2009-03-10 | Boston Scientific Scimed, Inc. | Block copolymer particles |
| US20080305176A1 (en) * | 2006-01-24 | 2008-12-11 | Biocompatibles Uk Limited | Process For Loading Polymer Particles With Drug |
| EP2520287B1 (de) * | 2006-02-10 | 2025-03-26 | Boston Scientific Medical Device Limited | Beladung von hydrophoben arzneimitteln in hydrophile polymer-abgabesysteme |
| US8062673B2 (en) | 2006-04-11 | 2011-11-22 | E I Du Pont De Nemours And Company | Process for embolization using swellable and deformable microspheres |
| US8252339B2 (en) | 2006-04-11 | 2012-08-28 | Massachusetts Institute Of Technology | Medical treatment applications of swellable and deformable microspheres |
| US7794755B2 (en) | 2006-04-11 | 2010-09-14 | E.I. Du Pont De Nemours And Company | Process for preparation of swellable and deformable microspheres |
| US7838035B2 (en) | 2006-04-11 | 2010-11-23 | E. I. Du Pont De Nemours And Company | Microsphere powder of high density, swellable, deformable, durable occlusion-forming microspheres |
| WO2009086076A2 (en) * | 2007-12-28 | 2009-07-09 | Boston Scientific Scimed, Inc. | Particles for injection and processes for forming the same |
| JP2011519870A (ja) * | 2008-05-21 | 2011-07-14 | テイコク ファーマ ユーエスエー インコーポレーテッド | 非ステロイド性抗炎症薬の経皮投与による月経困難症の治療 |
| US8202531B2 (en) * | 2008-07-23 | 2012-06-19 | Warsaw Orthopedic, Inc. | Drug depots having one or more anchoring members |
| US10071181B1 (en) | 2015-04-17 | 2018-09-11 | Teleflex Innovations S.À.R.L. | Resorbable embolization spheres |
| WO2022047544A1 (en) * | 2020-09-04 | 2022-03-10 | IP Cornerstone Pty Ltd | Minimally invasive treatment of osteoarthritis and other conditions |
| CN113855810A (zh) * | 2021-09-22 | 2021-12-31 | 西安纳瑞工控科技有限公司 | 一种药用辅料聚苯乙烯磺酸钠微球及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999012577A1 (en) * | 1997-09-05 | 1999-03-18 | Nycomed Imaging As | Polymer particles made of polyvinyl alcohol and comprising a contrast agent for chemoembolization |
| FR2784580B1 (fr) * | 1998-10-16 | 2004-06-25 | Biosepra Inc | Microspheres de polyvinyl-alcool et procedes de fabrication de celles-ci |
| US6562330B1 (en) * | 1998-11-13 | 2003-05-13 | Biocompatibles Limited | Therapeutic use of polymers |
| EP1263803B1 (de) * | 2000-03-13 | 2007-09-19 | BioCure, Inc. | Embolische zusammensetzungen |
-
2004
- 2004-02-23 US US10/546,723 patent/US20060057198A1/en not_active Abandoned
- 2004-02-23 CA CA002516736A patent/CA2516736A1/en not_active Abandoned
- 2004-02-23 DE DE602004010492T patent/DE602004010492T2/de not_active Expired - Lifetime
- 2004-02-23 AT AT04713577T patent/ATE380019T1/de not_active IP Right Cessation
- 2004-02-23 WO PCT/GB2004/000698 patent/WO2004073688A1/en not_active Ceased
- 2004-02-23 ES ES04713577T patent/ES2298724T3/es not_active Expired - Lifetime
- 2004-02-23 EP EP04713577A patent/EP1594472B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE602004010492D1 (de) | 2008-01-17 |
| EP1594472A1 (de) | 2005-11-16 |
| CA2516736A1 (en) | 2004-09-02 |
| US20060057198A1 (en) | 2006-03-16 |
| DE602004010492T2 (de) | 2008-11-13 |
| ES2298724T3 (es) | 2008-05-16 |
| EP1594472B1 (de) | 2007-12-05 |
| WO2004073688A1 (en) | 2004-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE380019T1 (de) | Abgabe eines nsaid aus embolischen mitteln | |
| AR038375A1 (es) | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo | |
| ES2524556T3 (es) | Composiciones farmacéuticas | |
| Fichorova et al. | Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives | |
| BRPI0513921A (pt) | composição para cuidado oral, e, método para liberar um ativo para cuidado oral | |
| Elavarasu et al. | Host modulation by therapeutic agents | |
| Schultzberg et al. | Inflammation in the nervous system—physiological and pathophysiological aspects | |
| Craft et al. | Antinociception produced by nonsteroidal anti-inflammatory drugs in female vs male rats | |
| Carlos et al. | Protective effect of low-level laser therapy (LLLT) on acute zymosan-induced arthritis | |
| ES2569477T3 (es) | Combinación de un inhibidor de HDAC y un antimetabolito | |
| UA27848C2 (uk) | Лікарська форма, що перорально вводиться, для лікування центральних станів дефіциту допаміну | |
| EA201000617A1 (ru) | Комбинация, включающая производные пурина и другие соединения, и ее применение для лечения воспалительных и обструктивных заболеваний дыхательных путей | |
| JP2011093898A (ja) | 眼科組成物 | |
| WO2006013376A3 (en) | Drug delivery of a cox inhibitor from embolic agents | |
| Motavallian et al. | Anti-inflammatory effects of alosetron mediated through 5-HT3 receptors on experimental colitis | |
| Lorenz et al. | IFN regulatory factor 4 controls post-ischemic inflammation and prevents chronic kidney disease | |
| Huang et al. | The mechanism of efferocytosis in the pathogenesis of periodontitis and its possible therapeutic strategies | |
| Arab et al. | Targeting inflammation and redox perturbations by lisinopril mitigates Freund’s adjuvant-induced arthritis in rats: Role of JAK-2/STAT-3/RANKL axis, MMPs, and VEGF | |
| ES2516644T3 (es) | Producto farmacéutico | |
| Dutra et al. | Inhibitor of PI3Kγ ameliorates TNBS‐induced colitis in mice by affecting the functional activity of CD4+ CD25+ FoxP3+ regulatory T cells | |
| Sheng et al. | Insights of efferocytosis in normal and pathological pregnancy | |
| AR043418A1 (es) | Formulaciones liquidas de las proteinas de union del factor necrosis del tumor | |
| RU2003100874A (ru) | Болеутоляющие и противовоспалительные составы, содержащие ингибиторы циклооксигеназы-2 | |
| Bédouet et al. | Tunable delivery of niflumic acid from resorbable embolization microspheres for uterine fibroid embolization | |
| Jain et al. | Design, characterization, and evaluation of meloxicam gel prepared by suspension and solution polymerization using solubility parameter as the basis for development |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |